Program
enozertinib
Also written as “ORIC-114”, “ORIC-114 Dose 1 + amivantamab” and “ORIC-114 Dose 2 + amivantamab”.
Its studies are mostly in Breast Neoplasms, led by ORIC Pharmaceuticals.
Furthest: phase 2, since Mar 24, 20223 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| ORIC Pharmaceuticals | 32 open or running | phase 2since Mar 24, 2022 | Mar 24, 2022 | Dec 2026phase 1 · NCT06816992 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2022First study: phase 2 study in Breast NeoplasmsFirst studyNCT05315700 · 350 planned · United States, Australia, Canada and more
- Aug 17, 2023Phase 1 study in Food Effect in Healthy ParticipantsNCT06012721 · 32 enrolled · Australia
- Feb 3, 2025Phase 1 study in Solid TumorsNCT06816992 · 76 planned · United States, Australia, Canada
Ahead
- Dec 2026Primary completion: phase 1 study in Solid TumorsNCT06816992
- Jun 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05315700
TargetBeta
“An orally bioavailable, central nervous system (CNS) penetrating, mutant-selective covalent inhibitor of epidermal growth factor receptor (EGFR; ErbB1) and human epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2) alterations, including exon 20 insertion (Ex20ins) mutations, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| EGFR/HER2 Mutant-selective Inhibitor BH-30643rule | blossomhill-therapeutics | phase 2 | 1 |
| GENSCI139rule | Changchun GeneScience Pharmaceutical | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06816992Solid Tumors · United States, Australia, Canada | 1 | Recruiting | Dec 2026 | 76 |
| NCT06012721Food Effect in Healthy Participants · Australia | 1 | Completed | Nov 23, 2023 | 32 |
| NCT05315700Breast Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Jun 2027 | 350 |
How it is read
Names in the registry
- “ORIC-114”, 2 entries
- “ORIC-114 Dose 1 + amivantamab”, 1 entry
- “ORIC-114 Dose 2 + amivantamab”, 1 entry
- “ORIC-114 Dose 3 + amivantamab”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.